$RNGE
RANGE IMPACT, INC.

2014 Q4 Form 10-Q Financial Statement

#000114420414068924 Filed on November 14, 2014

View on sec.gov

Income Statement

Concept 2014 Q4 2014 Q3 2014 Q1
Revenue $60.00K $86.70K $0.00
YoY Change
Cost Of Revenue $20.00K $22.11K
YoY Change
Gross Profit $40.00K $64.59K
YoY Change
Gross Profit Margin 66.67% 74.5%
Selling, General & Admin $670.0K $940.0K $790.0K
YoY Change -20.24% 28.77%
% of Gross Profit 1675.0% 1455.36%
Research & Development $370.0K $207.7K $30.00K
YoY Change 68.61% 107.34%
% of Gross Profit 925.0% 321.51%
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.030M $1.151M $820.0K
YoY Change -2.61% 38.06%
Operating Profit -$990.0K -$1.086M
YoY Change -6.39% 30.31%
Interest Expense -$150.0K $4.055K -$610.0K
YoY Change -268.84% -90.19%
% of Operating Profit
Other Income/Expense, Net -$321.7K
YoY Change -721.74%
Pretax Income -$1.140M -$1.410M -$1.430M
YoY Change 8.57% 80.77%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$1.140M -$1.408M -$1.430M
YoY Change 9.09% 80.09%
Net Earnings / Revenue -1900.0% -1623.79%
Basic Earnings Per Share
Diluted Earnings Per Share -$0.16 -$0.21 -$0.22
COMMON SHARES
Basic Shares Outstanding 72.43M shares 67.21M shares 66.43M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q4 2014 Q3 2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.050M $1.780M $1.400M
YoY Change -42.62% 223.64%
Cash & Equivalents $1.782M $1.403M
Short-Term Investments
Other Short-Term Assets $10.00K $20.00K $20.00K
YoY Change -80.0% -75.0%
Inventory $30.00K $19.42K $0.00
Prepaid Expenses $21.46K $10.64K
Receivables $40.00K $39.40K $0.00
Other Receivables $0.00 $0.00
Total Short-Term Assets $1.140M $1.860M $1.424M
YoY Change -39.51% 190.63% 169.24%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00
YoY Change
Total Long-Term Assets $0.00 $2.454K $0.00
YoY Change -100.0%
TOTAL ASSETS
Total Short-Term Assets $1.140M $1.860M $1.424M
Total Long-Term Assets $0.00 $2.454K $0.00
Total Assets $1.140M $1.862M $1.424M
YoY Change -39.51% 191.01% 164.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $140.0K $200.0K $80.00K
YoY Change -17.65% 81.82%
Accrued Expenses $0.00
YoY Change -100.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.630M $1.540M $1.535M
YoY Change 50.36% 3.36% 191.14%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.630M $1.540M $1.535M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.630M $1.543M $1.535M
YoY Change -0.02% -26.51% 38.58%
SHAREHOLDERS EQUITY
Retained Earnings -$10.39M -$8.327M
YoY Change -277.46% 99.49%
Common Stock $72.43K $66.83K
YoY Change 20.08%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$490.0K $319.1K -$110.4K
YoY Change
Total Liabilities & Shareholders Equity $1.140M $1.862M $1.424M
YoY Change -39.51% 191.01% 164.05%

Cashflow Statement

Concept 2014 Q4 2014 Q3 2014 Q1
OPERATING ACTIVITIES
Net Income -$1.140M -$1.408M -$1.430M
YoY Change 9.09% 80.09%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$730.0K -$520.0K -$530.0K
YoY Change 15.87% -14.75%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $1.471M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 1.470M 110.0K
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -730.0K -520.0K -530.0K
Cash From Investing Activities 0.000 0.000 0.000
Cash From Financing Activities 0.000 1.470M 110.0K
Net Change In Cash -730.0K 950.0K -420.0K
YoY Change -157.48% -255.74%
FREE CASH FLOW
Cash From Operating Activities -$730.0K -$520.0K -$530.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.03
CY2014Q1 us-gaap Cash
Cash
1403403 USD
CY2014Q3 us-gaap Cash
Cash
1782177 USD
CY2014Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0 USD
CY2014Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
39396 USD
CY2014Q1 us-gaap Inventory Net
InventoryNet
0 USD
CY2014Q3 us-gaap Inventory Net
InventoryNet
19417 USD
CY2014Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
21464 USD
CY2014Q3 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
0 USD
CY2014Q1 us-gaap Assets
Assets
1424453 USD
CY2014Q3 us-gaap Assets
Assets
1862454 USD
CY2014Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
79915 USD
CY2014Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
203458 USD
CY2014Q1 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
16100 USD
CY2014Q3 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
1000 USD
CY2014Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1438814 USD
CY2014Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1338849 USD
CY2014Q1 us-gaap Liabilities
Liabilities
1534829 USD
CY2014Q3 us-gaap Liabilities
Liabilities
1543307 USD
CY2014Q1 us-gaap Common Stock Value
CommonStockValue
66833 USD
CY2014Q3 us-gaap Common Stock Value
CommonStockValue
72430 USD
CY2014Q1 us-gaap Deferred Compensation Equity
DeferredCompensationEquity
149714 USD
CY2014Q3 us-gaap Deferred Compensation Equity
DeferredCompensationEquity
404034 USD
CY2014Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
8299366 USD
CY2014Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
11041158 USD
CY2014Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-8326861 USD
CY2014Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-10390407 USD
CY2014Q1 us-gaap Stockholders Equity
StockholdersEquity
-110376 USD
CY2014Q3 us-gaap Stockholders Equity
StockholdersEquity
319147 USD
CY2014Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1424453 USD
CY2014Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1862454 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><u><font style="FONT-SIZE: 10pt">Use of Estimates and Assumptions</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of a<font style="COLOR: black">ssets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. The more significant estimates and assumptions by management include, among others, the fair value of shares issued for services, the fair&#160;value of options and warrants, and assumptions used in the valuation of our outstanding derivative liabilities.</font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
us-gaap Derivatives Reporting Of Derivative Activity
DerivativesReportingOfDerivativeActivity
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><u><font style="FONT-SIZE: 10pt">Derivative Financial Instruments</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a probability weighted average Black-Scholes-Merton model to value the derivative instruments at inception and on subsequent valuation dates through the September 30, 2014 reporting date. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
72430100 shares
us-gaap Incremental Common Shares Attributable To Contingently Issuable Shares
IncrementalCommonSharesAttributableToContingentlyIssuableShares
999328 shares
CY2014Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
3000 USD
CY2014Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
525000000 shares
CY2014Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
525000000 shares
CY2014Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
66832523 shares
CY2014Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
66832523 shares
CY2014Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
72430100 shares
CY2014Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
14250 USD
us-gaap Officers Compensation
OfficersCompensation
95000 USD
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5150000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
450000 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
50000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
25000 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5525000 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4935420 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.26
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.40
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.10
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
0.47
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.32
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.30
stvf Weighted Average Remaining Vesting Period
WeightedAverageRemainingVestingPeriod
P2Y
stvf Unamortized Cost Stock Awards
UnamortizedCostStockAwards
152921 USD
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
320500 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
665873 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
121721 USD
CY2014Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
318500 USD
CY2014Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
7727129 shares
stvf Warrants Granted In Period
WarrantsGrantedInPeriod
8076472 shares
stvf Warrants Exercised In Period
WarrantsExercisedInPeriod
3676472 shares
stvf Warrants Cancelled In Period
WarrantsCancelledInPeriod
0 shares
CY2014Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
12127129 shares
CY2014Q3 stvf Warrants Exercisable
WarrantsExercisable
12127129 shares
CY2014Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.41
stvf Warrants Granted Period In Weighted Exercise Price
WarrantsGrantedPeriodInWeightedExercisePrice
0.37
stvf Warrants Cancelled In Period Weighted Exercise Price
WarrantsCancelledInPeriodWeightedExercisePrice
0
CY2014Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.39
stvf Warrants Exercisable Period In Weighted Exercisable Price
WarrantsExercisablePeriodInWeightedExercisablePrice
0.39
CY2014 stvf Warrants Granted Period In Weighted Exercise Price
WarrantsGrantedPeriodInWeightedExercisePrice
0.42
CY2013Q2 stvf Number Of Common Stock To Be Issued Upon Exercise Of Warrants
NumberOfCommonStockToBeIssuedUponExerciseOfWarrants
11029416 pure
CY2014Q3 stvf Number Of Common Stock To Be Issued Upon Exercise Of Warrants
NumberOfCommonStockToBeIssuedUponExerciseOfWarrants
4400000 pure
CY2014Q3 stvf Aggregate Intrinsic Value Of Warrants Outstanding
AggregateIntrinsicValueOfWarrantsOutstanding
104000 USD
CY2014 stvf Exercise Of Warrants Value
ExerciseOfWarrantsValue
3676472 USD
stvf Exercise Of Warrants Value
ExerciseOfWarrantsValue
3676472 USD
us-gaap Revenues
Revenues
0 USD
us-gaap Revenues
Revenues
128136 USD
CY2013Q3 us-gaap Revenues
Revenues
0 USD
CY2014Q3 us-gaap Revenues
Revenues
86695 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
0 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
33981 USD
CY2013Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
0 USD
CY2014Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
22106 USD
us-gaap Gross Profit
GrossProfit
0 USD
us-gaap Gross Profit
GrossProfit
94155 USD
CY2013Q3 us-gaap Gross Profit
GrossProfit
0 USD
CY2014Q3 us-gaap Gross Profit
GrossProfit
64589 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1427514 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1499726 USD
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
701318 USD
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
933060 USD
us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
73100 USD
us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
30217 USD
CY2013Q3 us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
31950 USD
CY2014Q3 us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
9900 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
223395 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
453643 USD
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
100156 USD
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
207663 USD
us-gaap Operating Expenses
OperatingExpenses
1724009 USD
us-gaap Operating Expenses
OperatingExpenses
1983586 USD
CY2013Q3 us-gaap Operating Expenses
OperatingExpenses
833424 USD
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
1150623 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-1724009 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-1889431 USD
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-833424 USD
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1086034 USD
us-gaap Interest Expense
InterestExpense
235087 USD
us-gaap Interest Expense
InterestExpense
4712 USD
CY2013Q3 us-gaap Interest Expense
InterestExpense
41346 USD
CY2014Q3 us-gaap Interest Expense
InterestExpense
4055 USD
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
278111 USD
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
792364 USD
CY2013Q3 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
93090 USD
CY2014Q3 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
644107 USD
us-gaap Net Income Loss
NetIncomeLoss
-1680985 USD
us-gaap Net Income Loss
NetIncomeLoss
-2063546 USD
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-781680 USD
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-1407749 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.03
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
30950 USD
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
203680 USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
144100 USD
CY2014 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
73100 USD
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
57898055 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
67356536 shares
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
59784168 shares
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
68630355 shares
CY2014Q1 us-gaap Share Price
SharePrice
0.41
CY2014Q3 us-gaap Share Price
SharePrice
0.33
us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0178 pure
CY2014 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.9215 pure
us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.8445 pure
CY2012Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5000 USD
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
203680 USD
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
144100 USD
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
121721 USD
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
665873 USD
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
121721 USD
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
28029 USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
216338 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-99 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
19417 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1400 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
10827 USD
us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
-62500 USD
us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
-10413 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1090 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
73543 USD
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-4319 USD
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-15100 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
18750 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
0 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-974415 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1107220 USD
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0 USD
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
10505 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
0 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
10505 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5000 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
1133250 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
0 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1133250 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1475489 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
158835 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
378774 USD
CY2013Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
392483 USD
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1403403 USD
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
551318 USD
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1782177 USD
us-gaap Interest Paid
InterestPaid
12075 USD
us-gaap Interest Paid
InterestPaid
4055 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
211250 USD
us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
0 USD
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
1249025 USD
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
0 USD
us-gaap Noncash Or Part Noncash Acquisition Accounts Receivable Acquired1
NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1
0 USD
us-gaap Noncash Or Part Noncash Acquisition Accounts Receivable Acquired1
NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1
39495 USD
us-gaap Stock Issued1
StockIssued1
0 USD
us-gaap Stock Issued1
StockIssued1
458000 USD
us-gaap Nature Of Operations
NatureOfOperations
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt"><strong>1. BUSINESS AND BASIS OF OPERATIONS</strong><font style="FONT-SIZE: 10pt">&#160;&#160;</font></font></b> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">Stevia First Corp. (the &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221; or &#8220;our&#8221;) was incorporated under the laws of the State of Nevada on June 29, 2007. In February 2012, we substantially changed our management team, added other key personnel, and began leasing laboratory and office space and land in California and since then we have been pursuing our new business as an agricultural biotechnology company engaged primarily in developing novel methods and technologies for industrial production of stevia, using such methods and technologies to develop, obtain approval for and commercialize one or more stevia extract products, and exploring and commercializing additional research applications for such methods and technologies.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; size: 8.5in 11.0in"> <strong>Going Concern</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">These financial statements have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. &#160;The Company has incurred losses and utilized cash in operations since inception resulting in an accumulated deficit of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10,390,407</font> as at September 30, 2014, and further losses are anticipated in the development of its business. These factors raise substantial doubt about the Company's ability to continue as a going concern. As a result, the Company&#8217;s independent registered public accounting firm, in their report on the Company&#8217;s March 31, 2014 audited&#160;financial statements, raised substantial doubt about the Company&#8217;s ability to continue as a going concern. These financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">The ability to continue as a going concern is dependent on the Company attaining and maintaining profitable operations in the future and/or raising additional capital to meet its obligations and repay its liabilities arising from normal business operations when they come due. We estimate that we will have sufficient funds to operate the business for the&#160;12 months&#160;after September 30, 2014.&#160;&#160;We will require additional financing to fund our planned long-term operations, including <font style="BACKGROUND-COLOR: transparent">our commitment under our new licensing agreement (See Note 9)</font>. These estimates could differ if we encounter unanticipated difficulties, in which case our current funds may not be sufficient to operate our business for that period. &#160;In addition, our estimates of the amount of cash necessary to operate our business may prove to be wrong, and we could spend our available financial resources much faster than we currently expect.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt">We do not have any firm commitments for future capital. &#160;Significant additional financing will be required to fund our planned principal operations in the near term and in future periods, including research and development activities relating to stevia extract production, developing and seeking regulatory approval for any of our stevia product candidates, commercializing any product candidate for which we are able to obtain regulatory approval or certification, seeking to license or acquire new assets or businesses, and maintaining our intellectual property rights and pursuing rights to new technologies. We do not presently have, nor do we expect in the near future to have, sufficient or consistent revenue to fund our business from our operations, and will need to obtain significant funding from external sources.&#160;&#160; Since inception, we have funded our operations primarily through equity and debt financings, and we expect to continue to rely on these sources of capital in the future. However, if we raise additional funds by issuing equity or convertible debt securities, our existing stockholders&#8217; ownership will be diluted, and obtaining commercial loans would increase our liabilities and future cash commitments. If we pursue capital through alternative sources, such as collaborations or other similar arrangements, we may be forced to relinquish rights to our proprietary technology or other intellectual property that could result in our receipt of only a portion of any revenue that may be generated from a partnered product or business. Further, these or other sources of capital may not be available on commercially reasonable or acceptable terms when needed, or at all. &#160;If we cannot raise the money that we need in order to continue to operate and&#160;develop our business, we will be forced to delay, scale back or eliminate some or all of our&#160;operations. &#160;If any of these were to occur, there is a substantial risk that our business would fail and our stockholders could lose all of their investment.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">Basis of Presentation of Unaudited Condensed Financial Information</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="COLOR: black">The unaudited condensed financial statements of the Company for the three and six months ended September 30, 2014 and 2013 have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information, applied on a consistent basis, and pursuant to the requirements for reporting on Form 10-Q and the requirements of Regulation S-K <font style="text-underline-style: double">and Regulation S-X promulgated under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;)</font>.&#160; Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States of America for complete audited financial statements.&#160;&#160;However, the information included in these financial statements reflects all adjustments (consisting solely of normal recurring adjustments), which are, in the opinion of management, necessary for the fair presentation of the Company&#8217;s financial position and the results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full fiscal year <font style="text-underline-style: double">or any future annual or interim period</font>.&#160;&#160;The balance sheet information as of March 31, 2014 was derived from the audited financial statements as of and for the year ended March 31, 2014 included in the Company&#8217;s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on June 30, 2014. These financial statements should be read in conjunction with that report.</font></div> </div> </div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2014-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Registrant Name
EntityRegistrantName
Stevia First Corp.
dei Entity Central Index Key
EntityCentralIndexKey
0001438943
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--03-31
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Trading Symbol
TradingSymbol
STVF
CY2014Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
72430100 shares
stvf Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
1470489 USD
stvf Warrants Exercised
WarrantsExercised
3676472 shares
CY2014Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1470589 USD
CY2014Q3 stvf Warrant Vesting Description
WarrantVestingDescription
These warrants have an exercise price of $0.30, and a term of ten years from issue date.Vesting terms of these warrants are as follows: (i)warrants to purchase 800,000 shares of common stock vested immediately at their grant date, (ii)warrants to purchase 2,000,000 shares of common stock have vesting terms ranging from one year to three years, and (iii)warrants to purchase 1,600,000 shares of common stock vest upon achievement of certain milestones under the distribution agreement
stvf Warrants Exercised Period In Weighted Exercise Price
WarrantsExercisedPeriodInWeightedExercisePrice
0.40
stvf Cost To Induce Exercise Of Warrants
CostToInduceExerciseOfWarrants
0 USD
stvf Cost To Induce Exercise Of Warrants
CostToInduceExerciseOfWarrants
961767 USD
CY2013Q3 stvf Cost To Induce Exercise Of Warrants
CostToInduceExerciseOfWarrants
0 USD
CY2014Q3 stvf Cost To Induce Exercise Of Warrants
CostToInduceExerciseOfWarrants
961767 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
278711 USD
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
278711 USD
us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
269368 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1470489 USD
us-gaap Liquidity Disclosure Sufficient Cash And Waivers Note
LiquidityDisclosureSufficientCashAndWaiversNote
We estimate that we will have sufficient funds to operate the business for the 12 months after September 30, 2014.
us-gaap Adjustment For Amortization
AdjustmentForAmortization
203680 USD
CY2014Q3 us-gaap Adjustment For Amortization
AdjustmentForAmortization
184757 USD
stvf Fair Value Of Warrants Exercise
FairValueOfWarrantsExercise
269368 USD
stvf Extinguishment Of Warrant Derivative Liabilities
ExtinguishmentOfWarrantDerivativeLiabilities
0 USD
stvf Extinguishment Of Warrant Derivative Liabilities
ExtinguishmentOfWarrantDerivativeLiabilities
269368 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
43024 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-174115 USD
CY2013Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
51744 USD
CY2014Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-321715 USD
CY2014Q3 stvf Annual Revenue Distribution And License Agreements
AnnualRevenueDistributionAndLicenseAgreements
5000000 USD
CY2014Q3 stvf Unamortized Cost Outstanding Warrants
UnamortizedCostOutstandingWarrants
830529 USD

Files In Submission

Name View Source Status
0001144204-14-068924-index-headers.html Edgar Link pending
0001144204-14-068924-index.html Edgar Link pending
0001144204-14-068924.txt Edgar Link pending
0001144204-14-068924-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
stvf-20140930.xml Edgar Link completed
stvf-20140930.xsd Edgar Link pending
stvf-20140930_cal.xml Edgar Link unprocessable
stvf-20140930_def.xml Edgar Link unprocessable
stvf-20140930_lab.xml Edgar Link unprocessable
stvf-20140930_pre.xml Edgar Link unprocessable
v392932_10q.htm Edgar Link pending
v392932_ex31-1.htm Edgar Link pending
v392932_ex32-1.htm Edgar Link pending